BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BioCentury  |  Strategy

Abbott takes AIM

Abbott invests $400M for chance to open therapeutic space with Reata's AIMs

A year after Abbott Laboratories paid almost half a billion dollars for rights to bardoxolone methyl from Reata Pharmaceuticals Inc., the pharma has doubled down to lock up access to hundreds of next-generation compounds with the same MOA but different pharmacological properties that may open up myriad new therapeutic areas for the class.

Abbott will pay $400 million up front for Reata's remaining antioxidant inflammation modulators (AIMs), which activate nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2) to trigger antioxidant and anti-inflammatory effects in diseased tissue. The compounds are in preclinical development.

The pharma licensed rights to the first-generation AIM bardoxolone methyl outside the U.S. and Asia for cardiovascular and metabolic indications in September 2010 for $450 million up front and up to $350 million in milestones, plus royalties. At the time, the compound was in Phase IIb testing to treat chronic kidney disease (CKD) in Type II diabetes patients (see BioCentury, Oct. 11, 2010).

Phase IIb data reported in December 2010 showed that once-daily bardoxolone methyl (formerly RTA 402) met the primary endpoint of increased glomerular filtration rate from baseline to week 24 vs. placebo (10.1 vs. 0.1 mL/min/1.73 m2, p<0.0001).

Bardoxolone methyl is now in Phase...

Read the full 996 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >